Incidence of co-infections and superinfections in hospitalized patients with COVID-19 : a retrospective cohort study
Copyright © 2020 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved..
OBJECTIVES: To describe the burden, epidemiology and outcomes of co-infections and superinfections occurring in hospitalized patients with coronavirus disease 2019 (COVID-19).
METHODS: We performed an observational cohort study of all consecutive patients admitted for ≥48 hours to the Hospital Clinic of Barcelona for COVID-19 (28 February to 22 April 2020) who were discharged or dead. We describe demographic, epidemiologic, laboratory and microbiologic results, as well as outcome data retrieved from electronic health records.
RESULTS: Of a total of 989 consecutive patients with COVID-19, 72 (7.2%) had 88 other microbiologically confirmed infections: 74 were bacterial, seven fungal and seven viral. Community-acquired co-infection at COVID-19 diagnosis was uncommon (31/989, 3.1%) and mainly caused by Streptococcus pneumoniae and Staphylococcus aureus. A total of 51 hospital-acquired bacterial superinfections, mostly caused by Pseudomonas aeruginosa and Escherichia coli, were diagnosed in 43 patients (4.7%), with a mean (SD) time from hospital admission to superinfection diagnosis of 10.6 (6.6) days. Overall mortality was 9.8% (97/989). Patients with community-acquired co-infections and hospital-acquired superinfections had worse outcomes.
CONCLUSIONS: Co-infection at COVID-19 diagnosis is uncommon. Few patients developed superinfections during hospitalization. These findings are different compared to those of other viral pandemics. As it relates to hospitalized patients with COVID-19, such findings could prove essential in defining the role of empiric antimicrobial therapy or stewardship strategies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases - 27(2021), 1 vom: 01. Jan., Seite 83-88 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Garcia-Vidal, Carolina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-Bacterial Agents |
|---|
| Anmerkungen: |
Date Completed 31.12.2020 Date Revised 10.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.cmi.2020.07.041 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM313209197 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM313209197 | ||
| 003 | DE-627 | ||
| 005 | 20231225150059.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cmi.2020.07.041 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1043.xml |
| 035 | |a (DE-627)NLM313209197 | ||
| 035 | |a (NLM)32745596 | ||
| 035 | |a (PII)S1198-743X(20)30450-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Garcia-Vidal, Carolina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Incidence of co-infections and superinfections in hospitalized patients with COVID-19 |b a retrospective cohort study |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.12.2020 | ||
| 500 | |a Date Revised 10.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved. | ||
| 520 | |a OBJECTIVES: To describe the burden, epidemiology and outcomes of co-infections and superinfections occurring in hospitalized patients with coronavirus disease 2019 (COVID-19) | ||
| 520 | |a METHODS: We performed an observational cohort study of all consecutive patients admitted for ≥48 hours to the Hospital Clinic of Barcelona for COVID-19 (28 February to 22 April 2020) who were discharged or dead. We describe demographic, epidemiologic, laboratory and microbiologic results, as well as outcome data retrieved from electronic health records | ||
| 520 | |a RESULTS: Of a total of 989 consecutive patients with COVID-19, 72 (7.2%) had 88 other microbiologically confirmed infections: 74 were bacterial, seven fungal and seven viral. Community-acquired co-infection at COVID-19 diagnosis was uncommon (31/989, 3.1%) and mainly caused by Streptococcus pneumoniae and Staphylococcus aureus. A total of 51 hospital-acquired bacterial superinfections, mostly caused by Pseudomonas aeruginosa and Escherichia coli, were diagnosed in 43 patients (4.7%), with a mean (SD) time from hospital admission to superinfection diagnosis of 10.6 (6.6) days. Overall mortality was 9.8% (97/989). Patients with community-acquired co-infections and hospital-acquired superinfections had worse outcomes | ||
| 520 | |a CONCLUSIONS: Co-infection at COVID-19 diagnosis is uncommon. Few patients developed superinfections during hospitalization. These findings are different compared to those of other viral pandemics. As it relates to hospitalized patients with COVID-19, such findings could prove essential in defining the role of empiric antimicrobial therapy or stewardship strategies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Co-infections | |
| 650 | 4 | |a Mortality | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Superinfections | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 700 | 1 | |a Sanjuan, Gemma |e verfasserin |4 aut | |
| 700 | 1 | |a Moreno-García, Estela |e verfasserin |4 aut | |
| 700 | 1 | |a Puerta-Alcalde, Pedro |e verfasserin |4 aut | |
| 700 | 1 | |a Garcia-Pouton, Nicole |e verfasserin |4 aut | |
| 700 | 1 | |a Chumbita, Mariana |e verfasserin |4 aut | |
| 700 | 1 | |a Fernandez-Pittol, Mariana |e verfasserin |4 aut | |
| 700 | 1 | |a Pitart, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Inciarte, Alexy |e verfasserin |4 aut | |
| 700 | 1 | |a Bodro, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Morata, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Ambrosioni, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Grafia, Ignacio |e verfasserin |4 aut | |
| 700 | 1 | |a Meira, Fernanda |e verfasserin |4 aut | |
| 700 | 1 | |a Macaya, Irene |e verfasserin |4 aut | |
| 700 | 1 | |a Cardozo, Celia |e verfasserin |4 aut | |
| 700 | 1 | |a Casals, Climent |e verfasserin |4 aut | |
| 700 | 1 | |a Tellez, Adrian |e verfasserin |4 aut | |
| 700 | 1 | |a Castro, Pedro |e verfasserin |4 aut | |
| 700 | 1 | |a Marco, Francesc |e verfasserin |4 aut | |
| 700 | 1 | |a García, Felipe |e verfasserin |4 aut | |
| 700 | 1 | |a Mensa, Josep |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez, José Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Soriano, Alex |e verfasserin |4 aut | |
| 700 | 0 | |a COVID-19 Researchers Group |e verfasserin |4 aut | |
| 700 | 1 | |a Rico, Verónica |e investigator |4 oth | |
| 700 | 1 | |a Hernández-Meneses, Marta |e investigator |4 oth | |
| 700 | 1 | |a Agüero, Daiana |e investigator |4 oth | |
| 700 | 1 | |a Torres, Berta |e investigator |4 oth | |
| 700 | 1 | |a González, Ana |e investigator |4 oth | |
| 700 | 1 | |a de la Mora, Lorena |e investigator |4 oth | |
| 700 | 1 | |a Rojas, Jhon |e investigator |4 oth | |
| 700 | 1 | |a Linares, Laura |e investigator |4 oth | |
| 700 | 1 | |a Fidalgo, Berta |e investigator |4 oth | |
| 700 | 1 | |a Rodriguez, Natalia |e investigator |4 oth | |
| 700 | 1 | |a Nicolas, David |e investigator |4 oth | |
| 700 | 1 | |a Albiach, Laia |e investigator |4 oth | |
| 700 | 1 | |a Muñoz, José |e investigator |4 oth | |
| 700 | 1 | |a Almuedo, Alex |e investigator |4 oth | |
| 700 | 1 | |a Camprubí, Daniel |e investigator |4 oth | |
| 700 | 1 | |a Angeles Marcos, Ma |e investigator |4 oth | |
| 700 | 1 | |a Camprubí, Daniel |e investigator |4 oth | |
| 700 | 1 | |a Cilloniz, Catia |e investigator |4 oth | |
| 700 | 1 | |a Fernández, Sara |e investigator |4 oth | |
| 700 | 1 | |a Nicolas, Jose M |e investigator |4 oth | |
| 700 | 1 | |a Torres, Antoni |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases |d 1995 |g 27(2021), 1 vom: 01. Jan., Seite 83-88 |w (DE-627)NLM094580014 |x 1469-0691 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2021 |g number:1 |g day:01 |g month:01 |g pages:83-88 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cmi.2020.07.041 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2021 |e 1 |b 01 |c 01 |h 83-88 | ||